ArticlePediatrics2025
Clinician Preferences for Oseltamivir Use in Children With Influenza in the Outpatient Setting.
Article in Pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Influenza Antivirals: Do We Need More Evidence?Pediatrics · 2025Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProfessional societies recommend antiviral treatment of all children at high risk for severe or complicated influenza disease, regardless of symptom duration. However, outpatient antiviral prescribing practices are inconsistent. We aimed to assess pediatric clinicians' outpatient prescribing practices for oseltamivir in children with influenza.
methodsThis vignette-based study of pediatric clinicians was conducted from March to June 2024 at 7 US children's hospitals and their affiliated clinics. The survey included 4 clinical influenza vignettes, 3 of which represented scenarios warranting treatment per national recommendations. One vignette was randomized to explore the impact of symptom duration on treatment preferences. Our primary outcome was the proportion of vignettes for which respondents were likely, somewhat or extremely, to recommend oseltamivir.
resultsOf 1124 eligible participants, 452 (40.2%) responded to the survey. Successive wave analysis revealed no evidence of response bias. Participants were likely to recommend oseltamivir in 36.2% of cases, with variation among specialties (29.6% for emergency medicine, 37.2% for general pediatrics, and 48.6% for infectious diseases; P < .001) and among study sites from 28.6% to 50.7% (P = .018), adjusted for clustering. Longer symptom duration (2 vs 4 days) significantly decreased respondents' likelihood to recommend oseltamivir from 30.9% to 1.8% (P < .001).
conclusionsWe demonstrate considerable nonadherence to national influenza treatment recommendations and variability regarding the outpatient use of oseltamivir to treat children with influenza. This indicates uncertainty of the perceived benefit of oseltamivir in a relatively healthy pediatric population with non-severe disease. Treatment standardization in accordance with national guidelines and rigorous monitoring of subsequent outcomes is needed.
Indexed as
Identifiers
40796188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.